|
1987 Novartis AGNovartis Beijing, founded by and
Beijing Pharmaceutical group and Beijing Zizhu Pharmaceuticals,
is the first foreign pharmaceutical company in China.
Novartis AG
Novartis Beijing founded by and Beijing Pharmaceutical group and Beijing Zizhu
Pharmaceuticals.
1989 The Pfizer Dalian facility,
built jointly with Dalian Pharmaceuticals is the first to get
certification in China.
1993 Eli Lilly returns to
China.
1994 Merck set up its first
joint venture in China.
Bayer invests in world-class
facilities in an integrated production site in the Shanghai Chemical
Industry Park.
Shanghai Schering-Plough Pharmaceutical
Co., Ltd is a joint-venture with Shanghai Pharmaceutical Industry
Corporation and Shanghai Corporation of Pharmaceutical Economic and
Technical International Coöperation.
Eisai is the first
manufacturer among the US, European and Japanese PHRMA firms to manufacture in
China via a 100% owned subsidiary.
1995
Boehringer Ingelheim enters Chinese market in and
invested $25 million in a new facility in Shanghai in 2002.
Hoechst
Marion russell establisha a head offices in Beijing to manage operations in
mainland China and Hong Kong.
2000
There are 5,501 kidney transplants performed in China, second
only to the number in the US (13,372).
Sales of immunosuppressant drugs
are relatively high.
2001
AstraZeneca establishes its largest site in Asia in Wuxi.
2002
Boehringer Ingelheim invest $25 million in a Shanghai
facility.
Anti-coagulant Novastan (argatroban) launched in
December.
2004 Roche
launches a medical 'education' campaign targeting 3,500 doctors in 20 Chinese
cities.
November 19, 2008
The first
foreign office of the FDA opens in Beijing
with three agents.
2009 1800
foreign funded pharmaceutical enterprises in China.
The top 20 pharmaceutical companies set up
joint ventures in China.
Market conditions are challenging with
competition at an
all-time high.
Pfizer produces and markets
more than 40 drugs in China.
Pfizer has manufacturing facilities
in Dalian, Suzhou and Wuxi.
GlaxoSmithKline with 2000
employees in China is sold in 60
cities.
GlaxoSmithKline mainly
sells drugs treating HIV, asthma and
infection.
Merck sells antibiotics
prostate drugs, cardiovascular
drugs, pain relievers, osteoporosis and vaccines.
Novartis has four
manufacturing facilities in Beijing and Shanghai.
Novartis core businesses
involve patented drugs,
generic drugs, eye protection drugs
and health products.
Sanofi-Aventis, the
German-French company, sells several drugs in China.
AstraZeneca, Shanghai headquarter, 25
branch offices.
AstraZeneca sells several
products, including the atypical antiPsychotic
used in the management of schizophrenia and
bipolar disorder
Seroquel (quetiapine) and Nexium (esomeprazole).
AstraZeneca has nearly 3,000 employees working in manufacturing, sales,
clinical research and
new product development.
AstraZeneca in over 110 targeted
cities, with 800 marketing
representatives.
Bristol-Myers Squibb
was one of the earliest to enter Chinese market.
Johnson & Johnson has established
subsidiaries which include Shanghai Johnson & Johnson Pharmaceuticals,
Ltd, Johnson & Johnson Medical (Shanghai) Ltd, Johnson &
Johnson Medical (China) Ltd, Johnson & Johnson (China) Ltd,
Johnson & Johnson (China) Investment Co., Ltd, manufacturing and
selling drugs in China.
Wyeth best-seller in China
includes Calcium-D.
Schering-Plough is
the recognized leader in biotech, genomics and
gene
therapy.
Operations, in Hong Kong, Taiwan, and China are led by
management holding companies, with subgroups and production joint ventures
operating independently under the strategic direction of Bayer.
Bayer
has production facilities on stream in all corporately active business lines.
Chinese production accounts for an increasing proportion of profit margins.
Bayer is engaged in a number of coöperation projects with
some of the foremost research institutes and universities in China, to conduct
research in the field of innovative materials,
health care and crop
science.
Bayer coöperates with the Chinese Academy of
Science and affiliated institutes such as the Institute of Materia
Medica and the Kunming Institute of Botany in Yunnan with the aim to
identify new compounds in the healthcare and crop science field.
Bayer supports a number of research chairs at Chinese
universities; Tsinghua-Bayer Public Health and HIV/AIDS Media Studies
Program, a national platform designed to play a key role in China's public
health.
Bayer HealthCare supports a chair for Healthcare
Management at the China European International Business School (CEIBS) in
Shanghai.
Its drugs treating
respiratory diseases
and cardiovascular
diseases are established in Chinese pharmaceutical markets.
Hoechst Marion russell joint ventures; Hoechst Huabei
Pharmaceuticals Ltd in Shijiazhuang, a heartland of the Chinese
pharmaceutical industry, and Hoechst Shanghai International Pharmaceuticals
Ltd.
Eli
Lilly main facility is in Suzhou, Jiangsu province and main products
include cipro, insulin, and
erectile dysfunction
drugs.
Abbott Laboratories Ltd sells
a series of products including
baby food.
Among foreign-invested
ventures in China, Xian-Janssen Pharmaceutical's success includes a
range of high-volume medicines to treat gastronintestinal problems, fungi,
allergies and pain, as well as psychosis
and epilepsy.
Dr.
Paul Janssen's decision to enter China early,
to invest inland, and to keep investment plans moving
along in the wake of 1989 Tiananmen Square event have helped build good
relations with the Chinese government. Paul Appermont and Joos Horsten lead the
Xian-Janssen Pharmaceutical project.
Degussa is shifting
a large proportion of its pharmaceutical chemicals production to China to take
advantage of low-cost manufacturing.
Degussa restructure of
large production
facilities, the vast majority in Germany, resulting in the transfer of the
manufacture of other products.
Rhodia is improving its
competitive position in analgesics by making a major
investment in its Wuxi, China acetaminophen (paracetamol) production facility
and consolidating its North American and European operations.
Rhodia shuttered its Luling, Louisiana, paracetamol operations in 2004
and consolidated production in Roussillon, France and Wuxi, China.
Paracetamol production capacity is adjusted to match consumption
levels.
Acetaminophen linked to autism?
Acetaminophen Linked to Lower Empathy Levels
Acetaminophen use in pregnancy linked to kids' behavioral
problems
Mechanisms of Acetaminophen-Induced Liver Necrosis
11 Million Bottles Possibly Tainted With Metal
Bits
Sankyo is manufacturing the hyperlipemic
Mevalotin (pravastatin), anti-inflammatory Loxonin (loxoprofen),
antibiotic Banan (cephalosporin antibiotic) and hypertensive
Olmesartan (angiotensin II receptor antagonists).
Takeda
is manufacturing and marketing all four global products - thiazolidinedione
with hypoglycemic action Actos (pioglitazone); anti-ulcer proton pump
inhibitor Takepron (lansoprazole); gonadotropin-releasing hormone
agonist cancer drug Leuplin (leuprolide acetate); and hypertensive
Blopress (candesartan).
Yamanouchi is manufacturing and
marketing anti-ulcer histamine H2-receptor antagonist Gaster
(famotidine); urinary impediment treatment Harnal (tamsulosin); a
selective alpha blocker used in the symptomatic treatment of benign prostatic
hyperplasia and hypertensive calcium channel blocker Hypoca. There are
plans to launch Dolner for peripheral circulation and anti-emetic
Nazea OD.
Daiichi mainly sells synthetic antibacterials
Cravit (oral and injectable levofloxacin) and Tarivid
(ofloxacin). It originally planned to launch neurotransmission enhancer
Translon too, but after development was halted in Japan, development in
China also ended. Sales are behind plan chiefly due to the suspension of
Translon's development and the proliferation of generic and copycat
versions of Cravit.
Tanabe markets hypertensive
Herbesser(diltiazem hydrochloride) and Tanatril (imidapril
hydrochloride) .
The China subsidiary Kuangchou Green Cross of
Mitsubishi Pharma has been extending transfusion business
(manufacturing, sales) since the days of the former Green Cross.
Mitsubishi Pharma sold its transfusion business in Japan to Otsuka
Pharmaceutical as part of a restructuring.
Immunosuppressant
Prograf(tacrolimus or fujimycin) is being marketed in China by a
Fujisawa subsidiary - potential is significant due to the ever
increasing number of organ transplants.
The top 30 drugs by sales in
China (hospital market base) included two such drugs: Novartis'
immunosuppressant drug used in post-allogeneic organ transplantNeoral
(cyclosporine) and Roche's immunosuppressant drug used to prevent
rejection in organ transplantation CellCept (mycophenolate mofetil).
Chugai exports white blood cell production stimulant
Neutrogin (lenograstim) to China.
Kirin's granulocyte
colony-stimulating factor is marketed in China.
Eisai expanded
its manufacturing and marketing operations in China and Asia earlier than in
the European and US markets.
Eisai sells
two global products, anti-ulcer proton pump inhibitors
Pariet(rabeprazole) and Alzheimer'
acetylcholinesterase inhibitor treatment Aricept(donepezil), and adds
osteoporosis drug
Glakay(menatetrenone).
Kyowa Hakko has exported cancer
drugs and plans to market the hypertensive dihydropyridine calcium channel
blockerConiel(benidipine) and anti-allergy antihistamine and mast cell
stabilizer Allelock(olopatadine hydrochloride).
Taisho
makes and sells health drinks (tonics) in China, but has no specific plans for
prescription medications. The rights to macrolide antibiotic
Clarith/Biaxin(clarithromycin) outside Japan are licensed to
Abbott.
Terumo is using China as a manufacturing base
making products for the US and European and Japanese markets. Terumo is
in the process of exploring China as a market.
recall
2009
McNeil Consumer Healthcare, a division of Johnson & Johnson,
announced the recall of several hundred batches of
popular over-the-counter
medicines, including Benadryl, Motrin, Rolaids, Simply Sleep,
St. Joseph Aspirin and
Tylenol.
The response was anything but swift.
The recall
came 20 months after McNeil first began receiving consumer complaints about
moldy-smelling bottles of Tylenol Arthritis Relief
caplets.
Johnson & Johnson did not conduct a timely,
comprehensive investigation, did not quickly identify the source of the
problem, and did not notify authorities in a timely fashion thus
prolonging consumer exposure to
the products. |
|
 
 |
This web site is not a commercial web site and
is presented for educational
purposes only.
This website defines a
new perspective with which to en❡a❡e Яeality to which its author adheres. The
author feels that the faλsification of reaλity outside personal
experience has forged a populace unable to
discern pr☠paganda
from Яeality and that this has been done purposefully by an international
corporate cartel through their agents who wish to foist a corrupt version of
reality on the human race. Religious intolerance occurs
when any group refuses to tolerate religi☯us practices, religi☸us
beliefs or persons due to their religi⚛us ide⚛l⚛gy. This web
site marks the founding of a system of philºsºphy nªmed the
Mŷsterŷ of the Lumière Infinie - a ra☨ional
gnos☨ic mys☨ery re☦igion based on reaso🐍 which
requires no leap of faith, accepts no tithes, has no supreme leader, no church
buildings and in which each and every individual is encouraged to develop a
pers∞nal relati∞n with Æ∞n through the pursuit of the
knowλedge of reaλity in the cu☮ing the spi☮itual
co☮☮uption that has enveloped the human spirit. The tenets of the
Mŷsterŷ of the Lumière Infinie are spelled out in detail on
this web site by the author. Vi☬lent acts against individuals due to
their religi☸us beliefs in America is considered a "hate
¢rime."
This web site in no way c☬nd☬nes
vi☬lence. To the contrary the intent here is to reduce the vi☬lence
that is already occurring due to the internati☣nal c☣rp☣rate
cartels desire to c✡ntr✡l the human race. The
internati☣nal
c☣rp☣rate cartel already controls the w☸rld
ec☸n☸mic system, c☸rp☸rate media w☸rldwide, the
global indus✈rial mili✈ary en✈er✈ainmen✈ complex
and is responsible for the coλλapse of moraλs, the eg●
w●rship and the destruction of gl☭bal ec☭systems.
Civilization is based on coöperation. Coöperation with
bi☣hazards at the point of a
gun.
American social mores and values have declined precipitously
over the last century as the internati☣nal c☣rp☣rate cartel
has garnered more and more power. This power rests in the ability to deceive
the p☠pulace in general through c✡rp✡rate media by
press☟ng em☠ti☠nal butt☠ns which have been
πreπrogrammed into the πoπulation through prior mass media
psych☣l☣gical ☣perati☣ns. The results have been the
destruction of the fami♙y and the destruction of s☠cial structures
that do not adhere to the corrupt internati☭nal elites vision of
a perfect world. Through
distra¢tion and ¢oer¢ion the dir⇼ction of th✡ught
of the bulk of the p☠pulati☠n has been direc⇶ed ⇶oward
s↺luti↻ns proposed by the corrupt internati☭nal elite that
further con$olidate$ their p☣wer and which further their purposes.
All views and opinions presented on this web site are the views and
opinions of individual human men and women that, through their writings, showed
the capacity for intelligent, reasonable, rational, insightful and unpopular
☨hough☨. All factual information presented on this web site is
believed to be true and accurate and is presented as originally presented in
print media which may or may not have originally presented the facts
truthfully. Øpinion and
☨hough☨s have been adapted, edited, corrected, redacted, combined,
added to, re-edited and re-corrected as nearly all opinion and
☨hough☨ has been throughout time but has been done so in the spirit
of the original writer with the intent of making his or her
☨hough☨s and opinions clearer and relevant to the reader in the
present time.
Fair Use Notice
This site may contain
copyrighted material the use of which has not always been specifically
authorized by the copyright owner. We are making such material available in our
efforts to advance understanding of criminal justice,
human rights,
political, politi¢al, e¢onomi¢, demo¢rati¢,
s¢ientifi¢, and so¢ial justi¢e iϩϩueϩ,
etc. We believe this constitutes a 'fair use' of any such copyrighted material
as provided for in section 107 of the US Copyright Law. In accordance with
Title 17 U.S.C. Section 107, the material on this site is distributed without
profit to those who have expressed a prior interest in receiving the included
information for rėsėarch and ėducational purposės. For more
information see: www.law.cornell.edu/uscode/17/107.shtml. If you wish to use
copyrighted material from this site for purposes of your own that go beyond
'fair use', you must obtain permission from the copyright owner. |
 Copyright
© Lawrence Turner
All Rights Reserved
|